NCT04034238View on ClinicalTrials.gov

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 29, 2019

Primary Completion Date

December 1, 2020

Study Completion Date

November 19, 2021

Conditions
Neoplasms With Mesothelin ExpressionEpithelioid MesotheliomaCholangiocarcinoma, ExtrahepaticAdenocarcinoma, Pancreatic
Interventions
DRUG

LMB-100

Arms 1 and 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.

DRUG

Tofacitinib

Arms 1 and 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.

DEVICE

Mesothelin Expression

Test for mesothelin expression in tumor tissues for study eligibility

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT04034238 - Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | Biotech Hunter | Biotech Hunter